Market Overview:
The global recombinant human granulocyte colony-stimulating market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for blood and blood products, and growing number of stem cell transplants. Based on type, the global recombinant human granulocyte colony-stimulating market is segmented into lenograstim (granocyte), filgrastim (neupogen, zarzio, nivestim, ratiograstim), and others. Lenograstim accounted for the largest share of the global recombinant human granulocyte colony-stimulating market in 2017 owing to its high usage in chemotherapy induced neutropenia and before blood donation applications. Filgrastim is expected to grow at a higher CAGR than other types during the forecast period due to its increasing use in stem cell transplants. Based on application, the global recombinant human granulocyte colony-stimulating market is segmented into chemotherapy induced neutropenia, before blood donation, stem cell transplants,, and others.
Product Definition:
A recombinant human granulocyte colony-stimulating factor (rhG-CSF) is a protein that is identical to the naturally occurring human G-CSF. It is used to stimulate the production of white blood cells, including neutrophils, in people with low white blood cell counts.
Lenograstim (Granocyte):
Lenograstim is a recombinant human granulocyte colony-stimulating factor. It is manufactured by the fusion of an Erythropoietin (EPO) molecule and a growth factor, which allows it to bind to the surface of certain cells in the immune system that are involved in fighting infections. Lenograstim has been approved by both U.S.
Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim):
Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim) is a type of interleukin used to stimulate the production of granulocytes by the bone marrow. It works by increasing the proliferation and differentiation of granulocytes.
Application Insights:
The chemotherapy induced neutropenia segment dominated the global market in terms of revenue share in 2017. This is due to an increase in number of cancer patients and a rise in the adoption of recombinant human granulocyte colony-stimulating factors for chemotherapy-induced neutropenia. Furthermore, there has been an increase in R&D activities pertaining to this application segment owing to growing awareness about stem cells and their benefits. For instance, according Granite Medical Inc announced that its GRANXLLT3 product is indicated for the treatment of adults with chemotherapy-induced low white blood cell count (WBC) or reduced WBCs after completion therapy with other than palliative intent drugs.
Regional Analysis:
North America dominated the global market in 2017. This is due to an increase in the number of clinical trials for blood disorders and cancer, which drives demand for granulocyte colony-stimulating factors. Moreover, a rise in stem cell transplantation procedures is also expected to fuel regional growth over the forecast period. Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to increasing incidence of chronic diseases such as leukemia and lymphoma that require treatment with chemotherapy or radiation therapy resulting in high demand for rHGCS products from this region.
Moreover, supportive government initiatives pertaining to manufacturing & export control policies are projected favorably impact regional market dynamics during future years ending up with 2030 CEV).
Growth Factors:
- Increasing incidence of cancer and other diseases requiring chemotherapy
- Growing demand for hematopoietic stem cells for transplantation
- Rising number of patients suffering from autoimmune diseases
- Increasing use of recombinant human granulocyte colony-stimulating factor in clinical trials
- Technological advancements in the field of recombinant human granulocyte colony-stimulating factor
Scope Of The Report
Report Attributes
Report Details
Report Title
Recombinant Human Granulocyte Colony-Stimulating Market Research Report
By Type
Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim), Others
By Application
Chemotherapy Induced Neutropenia, Before Blood Donation, Stem Cell Transplants, Others
By Companies
Amgen, Qilu Pharmaceutical, Shijiazhuang Pharmaceutical, Kyowa Hakko Kirin, Gensci, Amoytop Biotech, Hangzhou Jiuyuan, Huaxin, Triprime, Sinovac, Amgen, Kawin
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
218
Number of Tables & Figures
153
Customization Available
Yes, the report can be customized as per your need.
Global Recombinant Human Granulocyte Colony-Stimulating Market Report Segments:
The global Recombinant Human Granulocyte Colony-Stimulating market is segmented on the basis of:
Types
Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim), Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Chemotherapy Induced Neutropenia, Before Blood Donation, Stem Cell Transplants, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Qilu Pharmaceutical
- Shijiazhuang Pharmaceutical
- Kyowa Hakko Kirin
- Gensci
- Amoytop Biotech
- Hangzhou Jiuyuan
- Huaxin
- Triprime
- Sinovac
- Amgen
- Kawin
Highlights of The Recombinant Human Granulocyte Colony-Stimulating Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Lenograstim (Granocyte)
- Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
- Others
- By Application:
- Chemotherapy Induced Neutropenia
- Before Blood Donation
- Stem Cell Transplants
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Recombinant Human Granulocyte Colony-Stimulating Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is a protein produced by recombinant DNA technology. It is used to treat certain types of cancer and other diseases. RhG-CSF helps the body's white blood cells, called granulocytes, multiply and fight infection.
Some of the major players in the recombinant human granulocyte colony-stimulating market are Amgen, Qilu Pharmaceutical, Shijiazhuang Pharmaceutical, Kyowa Hakko Kirin, Gensci, Amoytop Biotech, Hangzhou Jiuyuan, Huaxin, Triprime, Sinovac, Amgen, Kawin.
The recombinant human granulocyte colony-stimulating market is expected to register a CAGR of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Recombinant Human Granulocyte Colony-Stimulating Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Recombinant Human Granulocyte Colony-Stimulating Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Recombinant Human Granulocyte Colony-Stimulating Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Recombinant Human Granulocyte Colony-Stimulating Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Recombinant Human Granulocyte Colony-Stimulating Market Size & Forecast, 2018-2028
4.5.1 Recombinant Human Granulocyte Colony-Stimulating Market Size and Y-o-Y Growth
4.5.2 Recombinant Human Granulocyte Colony-Stimulating Market Absolute $ Opportunity
Chapter 5 Global Recombinant Human Granulocyte Colony-Stimulating Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Type
5.2.1 Lenograstim (Granocyte)
5.2.2 Filgrastim (Neupogen
5.2.3 Zarzio
5.2.4 Nivestim
5.2.5 Ratiograstim)
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Recombinant Human Granulocyte Colony-Stimulating Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Applications
6.2.1 Chemotherapy Induced Neutropenia
6.2.2 Before Blood Donation
6.2.3 Stem Cell Transplants
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Recombinant Human Granulocyte Colony-Stimulating Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Recombinant Human Granulocyte Colony-Stimulating Analysis and Forecast
9.1 Introduction
9.2 North America Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Type
9.6.1 Lenograstim (Granocyte)
9.6.2 Filgrastim (Neupogen
9.6.3 Zarzio
9.6.4 Nivestim
9.6.5 Ratiograstim)
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Applications
9.10.1 Chemotherapy Induced Neutropenia
9.10.2 Before Blood Donation
9.10.3 Stem Cell Transplants
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Recombinant Human Granulocyte Colony-Stimulating Analysis and Forecast
10.1 Introduction
10.2 Europe Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Type
10.6.1 Lenograstim (Granocyte)
10.6.2 Filgrastim (Neupogen
10.6.3 Zarzio
10.6.4 Nivestim
10.6.5 Ratiograstim)
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Applications
10.10.1 Chemotherapy Induced Neutropenia
10.10.2 Before Blood Donation
10.10.3 Stem Cell Transplants
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Type
11.6.1 Lenograstim (Granocyte)
11.6.2 Filgrastim (Neupogen
11.6.3 Zarzio
11.6.4 Nivestim
11.6.5 Ratiograstim)
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Applications
11.10.1 Chemotherapy Induced Neutropenia
11.10.2 Before Blood Donation
11.10.3 Stem Cell Transplants
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Recombinant Human Granulocyte Colony-Stimulating Analysis and Forecast
12.1 Introduction
12.2 Latin America Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Type
12.6.1 Lenograstim (Granocyte)
12.6.2 Filgrastim (Neupogen
12.6.3 Zarzio
12.6.4 Nivestim
12.6.5 Ratiograstim)
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Applications
12.10.1 Chemotherapy Induced Neutropenia
12.10.2 Before Blood Donation
12.10.3 Stem Cell Transplants
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Recombinant Human Granulocyte Colony-Stimulating Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Type
13.6.1 Lenograstim (Granocyte)
13.6.2 Filgrastim (Neupogen
13.6.3 Zarzio
13.6.4 Nivestim
13.6.5 Ratiograstim)
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Applications
13.10.1 Chemotherapy Induced Neutropenia
13.10.2 Before Blood Donation
13.10.3 Stem Cell Transplants
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Recombinant Human Granulocyte Colony-Stimulating Market: Competitive Dashboard
14.2 Global Recombinant Human Granulocyte Colony-Stimulating Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 Qilu Pharmaceutical
14.3.3 Shijiazhuang Pharmaceutical
14.3.4 Kyowa Hakko Kirin
14.3.5 Gensci
14.3.6 Amoytop Biotech
14.3.7 Hangzhou Jiuyuan
14.3.8 Huaxin
14.3.9 Triprime
14.3.10 Sinovac
14.3.11 Amgen
14.3.12 Kawin
